Acrivon Therapeutics, Inc. Common Stock
Acrivon Therapeutics, Inc. Common Stock (ACRV) Stock Competitors & Peer Comparison
See (ACRV) competitors and their performances in Stock Market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| ACRV | $1.97 | +11.93% | 62.2M | -0.98 | -$2.02 | N/A |
| VRTX | $437.67 | +0.25% | 111.3B | 28.56 | $15.32 | N/A |
| REGN | $746.58 | -0.10% | 77.6B | 17.89 | $41.73 | +0.24% |
| VRNA | $106.91 | +0.11% | 72.7B | -102.80 | -$1.04 | N/A |
| ARGX | $793.22 | -1.51% | 49.1B | 40.45 | $19.61 | N/A |
| SGEN | $228.74 | -0.07% | 43.2B | -57.19 | -$4.00 | N/A |
| ALNY | $310.58 | +0.70% | 41.4B | 132.73 | $2.34 | N/A |
| INSM | $144.48 | +2.48% | 31.2B | -22.47 | -$6.43 | N/A |
| RVMD | $141.50 | -4.97% | 28B | -23.74 | -$5.96 | N/A |
| BNTX | $108.60 | -2.69% | 27.3B | -19.57 | -$5.55 | N/A |
Stock Comparison
ACRV vs VRTX Comparison April 2026
ACRV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACRV stands at 62.2M. In comparison, VRTX has a market cap of 111.3B. Regarding current trading prices, ACRV is priced at $1.97, while VRTX trades at $437.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACRV currently has a P/E ratio of -0.98, whereas VRTX's P/E ratio is 28.56. In terms of profitability, ACRV's ROE is -0.57%, compared to VRTX's ROE of +0.23%. Regarding short-term risk, ACRV is more volatile compared to VRTX. This indicates potentially higher risk in terms of short-term price fluctuations for ACRV.Check VRTX's competition here
ACRV vs REGN Comparison April 2026
ACRV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACRV stands at 62.2M. In comparison, REGN has a market cap of 77.6B. Regarding current trading prices, ACRV is priced at $1.97, while REGN trades at $746.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACRV currently has a P/E ratio of -0.98, whereas REGN's P/E ratio is 17.89. In terms of profitability, ACRV's ROE is -0.57%, compared to REGN's ROE of +0.15%. Regarding short-term risk, ACRV is more volatile compared to REGN. This indicates potentially higher risk in terms of short-term price fluctuations for ACRV.Check REGN's competition here
ACRV vs VRNA Comparison April 2026
ACRV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACRV stands at 62.2M. In comparison, VRNA has a market cap of 72.7B. Regarding current trading prices, ACRV is priced at $1.97, while VRNA trades at $106.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACRV currently has a P/E ratio of -0.98, whereas VRNA's P/E ratio is -102.80. In terms of profitability, ACRV's ROE is -0.57%, compared to VRNA's ROE of -0.13%. Regarding short-term risk, ACRV is more volatile compared to VRNA. This indicates potentially higher risk in terms of short-term price fluctuations for ACRV.Check VRNA's competition here
ACRV vs ARGX Comparison April 2026
ACRV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACRV stands at 62.2M. In comparison, ARGX has a market cap of 49.1B. Regarding current trading prices, ACRV is priced at $1.97, while ARGX trades at $793.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACRV currently has a P/E ratio of -0.98, whereas ARGX's P/E ratio is 40.45. In terms of profitability, ACRV's ROE is -0.57%, compared to ARGX's ROE of +0.34%. Regarding short-term risk, ACRV is more volatile compared to ARGX. This indicates potentially higher risk in terms of short-term price fluctuations for ACRV.Check ARGX's competition here
ACRV vs SGEN Comparison April 2026
ACRV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACRV stands at 62.2M. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, ACRV is priced at $1.97, while SGEN trades at $228.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACRV currently has a P/E ratio of -0.98, whereas SGEN's P/E ratio is -57.19. In terms of profitability, ACRV's ROE is -0.57%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, ACRV is more volatile compared to SGEN. This indicates potentially higher risk in terms of short-term price fluctuations for ACRV.Check SGEN's competition here
ACRV vs ALNY Comparison April 2026
ACRV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACRV stands at 62.2M. In comparison, ALNY has a market cap of 41.4B. Regarding current trading prices, ACRV is priced at $1.97, while ALNY trades at $310.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACRV currently has a P/E ratio of -0.98, whereas ALNY's P/E ratio is 132.73. In terms of profitability, ACRV's ROE is -0.57%, compared to ALNY's ROE of +0.90%. Regarding short-term risk, ACRV is more volatile compared to ALNY. This indicates potentially higher risk in terms of short-term price fluctuations for ACRV.Check ALNY's competition here
ACRV vs INSM Comparison April 2026
ACRV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACRV stands at 62.2M. In comparison, INSM has a market cap of 31.2B. Regarding current trading prices, ACRV is priced at $1.97, while INSM trades at $144.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACRV currently has a P/E ratio of -0.98, whereas INSM's P/E ratio is -22.47. In terms of profitability, ACRV's ROE is -0.57%, compared to INSM's ROE of -1.68%. Regarding short-term risk, ACRV is more volatile compared to INSM. This indicates potentially higher risk in terms of short-term price fluctuations for ACRV.Check INSM's competition here
ACRV vs RVMD Comparison April 2026
ACRV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACRV stands at 62.2M. In comparison, RVMD has a market cap of 28B. Regarding current trading prices, ACRV is priced at $1.97, while RVMD trades at $141.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACRV currently has a P/E ratio of -0.98, whereas RVMD's P/E ratio is -23.74. In terms of profitability, ACRV's ROE is -0.57%, compared to RVMD's ROE of -0.63%. Regarding short-term risk, ACRV is more volatile compared to RVMD. This indicates potentially higher risk in terms of short-term price fluctuations for ACRV.Check RVMD's competition here
ACRV vs BNTX Comparison April 2026
ACRV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACRV stands at 62.2M. In comparison, BNTX has a market cap of 27.3B. Regarding current trading prices, ACRV is priced at $1.97, while BNTX trades at $108.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACRV currently has a P/E ratio of -0.98, whereas BNTX's P/E ratio is -19.57. In terms of profitability, ACRV's ROE is -0.57%, compared to BNTX's ROE of -0.06%. Regarding short-term risk, ACRV is more volatile compared to BNTX. This indicates potentially higher risk in terms of short-term price fluctuations for ACRV.Check BNTX's competition here
ACRV vs UTHR Comparison April 2026
ACRV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACRV stands at 62.2M. In comparison, UTHR has a market cap of 25.2B. Regarding current trading prices, ACRV is priced at $1.97, while UTHR trades at $574.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACRV currently has a P/E ratio of -0.98, whereas UTHR's P/E ratio is 20.59. In terms of profitability, ACRV's ROE is -0.57%, compared to UTHR's ROE of +0.19%. Regarding short-term risk, ACRV is more volatile compared to UTHR. This indicates potentially higher risk in terms of short-term price fluctuations for ACRV.Check UTHR's competition here
ACRV vs MRNA Comparison April 2026
ACRV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACRV stands at 62.2M. In comparison, MRNA has a market cap of 22B. Regarding current trading prices, ACRV is priced at $1.97, while MRNA trades at $55.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACRV currently has a P/E ratio of -0.98, whereas MRNA's P/E ratio is -7.66. In terms of profitability, ACRV's ROE is -0.57%, compared to MRNA's ROE of -0.30%. Regarding short-term risk, ACRV is more volatile compared to MRNA. This indicates potentially higher risk in terms of short-term price fluctuations for ACRV.Check MRNA's competition here
ACRV vs RPRX Comparison April 2026
ACRV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACRV stands at 62.2M. In comparison, RPRX has a market cap of 21.3B. Regarding current trading prices, ACRV is priced at $1.97, while RPRX trades at $49.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACRV currently has a P/E ratio of -0.98, whereas RPRX's P/E ratio is 27.93. In terms of profitability, ACRV's ROE is -0.57%, compared to RPRX's ROE of +0.12%. Regarding short-term risk, ACRV is more volatile compared to RPRX. This indicates potentially higher risk in terms of short-term price fluctuations for ACRV.Check RPRX's competition here
ACRV vs ROIV Comparison April 2026
ACRV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACRV stands at 62.2M. In comparison, ROIV has a market cap of 20.9B. Regarding current trading prices, ACRV is priced at $1.97, while ROIV trades at $29.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACRV currently has a P/E ratio of -0.98, whereas ROIV's P/E ratio is -24.91. In terms of profitability, ACRV's ROE is -0.57%, compared to ROIV's ROE of -0.18%. Regarding short-term risk, ACRV is more volatile compared to ROIV. This indicates potentially higher risk in terms of short-term price fluctuations for ACRV.Check ROIV's competition here
ACRV vs BGNE Comparison April 2026
ACRV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACRV stands at 62.2M. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, ACRV is priced at $1.97, while BGNE trades at $184.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACRV currently has a P/E ratio of -0.98, whereas BGNE's P/E ratio is -22.55. In terms of profitability, ACRV's ROE is -0.57%, compared to BGNE's ROE of +0.07%. Regarding short-term risk, ACRV is more volatile compared to BGNE. This indicates potentially higher risk in terms of short-term price fluctuations for ACRV.Check BGNE's competition here
ACRV vs INCY Comparison April 2026
ACRV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACRV stands at 62.2M. In comparison, INCY has a market cap of 19.3B. Regarding current trading prices, ACRV is priced at $1.97, while INCY trades at $96.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACRV currently has a P/E ratio of -0.98, whereas INCY's P/E ratio is 15.09. In terms of profitability, ACRV's ROE is -0.57%, compared to INCY's ROE of +0.29%. Regarding short-term risk, ACRV is more volatile compared to INCY. This indicates potentially higher risk in terms of short-term price fluctuations for ACRV.Check INCY's competition here
ACRV vs SMMT Comparison April 2026
ACRV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACRV stands at 62.2M. In comparison, SMMT has a market cap of 19B. Regarding current trading prices, ACRV is priced at $1.97, while SMMT trades at $24.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACRV currently has a P/E ratio of -0.98, whereas SMMT's P/E ratio is -17.05. In terms of profitability, ACRV's ROE is -0.57%, compared to SMMT's ROE of -2.97%. Regarding short-term risk, ACRV is less volatile compared to SMMT. This indicates potentially lower risk in terms of short-term price fluctuations for ACRV.Check SMMT's competition here
ACRV vs DNA-WT Comparison April 2026
ACRV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACRV stands at 62.2M. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, ACRV is priced at $1.97, while DNA-WT trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACRV currently has a P/E ratio of -0.98, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, ACRV's ROE is -0.57%, compared to DNA-WT's ROE of -0.54%. Regarding short-term risk, ACRV is more volatile compared to DNA-WT. This indicates potentially higher risk in terms of short-term price fluctuations for ACRV.Check DNA-WT's competition here
ACRV vs GMAB Comparison April 2026
ACRV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACRV stands at 62.2M. In comparison, GMAB has a market cap of 17.1B. Regarding current trading prices, ACRV is priced at $1.97, while GMAB trades at $27.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACRV currently has a P/E ratio of -0.98, whereas GMAB's P/E ratio is 17.98. In terms of profitability, ACRV's ROE is -0.57%, compared to GMAB's ROE of +0.14%. Regarding short-term risk, ACRV is more volatile compared to GMAB. This indicates potentially higher risk in terms of short-term price fluctuations for ACRV.Check GMAB's competition here
ACRV vs BBIO Comparison April 2026
ACRV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACRV stands at 62.2M. In comparison, BBIO has a market cap of 14.4B. Regarding current trading prices, ACRV is priced at $1.97, while BBIO trades at $74.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACRV currently has a P/E ratio of -0.98, whereas BBIO's P/E ratio is -19.69. In terms of profitability, ACRV's ROE is -0.57%, compared to BBIO's ROE of +0.39%. Regarding short-term risk, ACRV is more volatile compared to BBIO. This indicates potentially higher risk in terms of short-term price fluctuations for ACRV.Check BBIO's competition here
ACRV vs ASND Comparison April 2026
ACRV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACRV stands at 62.2M. In comparison, ASND has a market cap of 14.2B. Regarding current trading prices, ACRV is priced at $1.97, while ASND trades at $231.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACRV currently has a P/E ratio of -0.98, whereas ASND's P/E ratio is -51.92. In terms of profitability, ACRV's ROE is -0.57%, compared to ASND's ROE of +1.28%. Regarding short-term risk, ACRV is more volatile compared to ASND. This indicates potentially higher risk in terms of short-term price fluctuations for ACRV.Check ASND's competition here
ACRV vs KRTX Comparison April 2026
ACRV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACRV stands at 62.2M. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, ACRV is priced at $1.97, while KRTX trades at $329.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACRV currently has a P/E ratio of -0.98, whereas KRTX's P/E ratio is -28.09. In terms of profitability, ACRV's ROE is -0.57%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, ACRV is more volatile compared to KRTX. This indicates potentially higher risk in terms of short-term price fluctuations for ACRV.Check KRTX's competition here
ACRV vs JAZZ Comparison April 2026
ACRV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACRV stands at 62.2M. In comparison, JAZZ has a market cap of 12.5B. Regarding current trading prices, ACRV is priced at $1.97, while JAZZ trades at $202.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACRV currently has a P/E ratio of -0.98, whereas JAZZ's P/E ratio is -34.66. In terms of profitability, ACRV's ROE is -0.57%, compared to JAZZ's ROE of -0.09%. Regarding short-term risk, ACRV is more volatile compared to JAZZ. This indicates potentially higher risk in terms of short-term price fluctuations for ACRV.Check JAZZ's competition here
ACRV vs IONS Comparison April 2026
ACRV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACRV stands at 62.2M. In comparison, IONS has a market cap of 12.4B. Regarding current trading prices, ACRV is priced at $1.97, while IONS trades at $74.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACRV currently has a P/E ratio of -0.98, whereas IONS's P/E ratio is -31.44. In terms of profitability, ACRV's ROE is -0.57%, compared to IONS's ROE of -0.69%. Regarding short-term risk, ACRV is more volatile compared to IONS. This indicates potentially higher risk in terms of short-term price fluctuations for ACRV.Check IONS's competition here
ACRV vs EXEL Comparison April 2026
ACRV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACRV stands at 62.2M. In comparison, EXEL has a market cap of 12.2B. Regarding current trading prices, ACRV is priced at $1.97, while EXEL trades at $46.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACRV currently has a P/E ratio of -0.98, whereas EXEL's P/E ratio is 16.85. In terms of profitability, ACRV's ROE is -0.57%, compared to EXEL's ROE of +0.37%. Regarding short-term risk, ACRV is more volatile compared to EXEL. This indicates potentially higher risk in terms of short-term price fluctuations for ACRV.Check EXEL's competition here
ACRV vs MDGL Comparison April 2026
ACRV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACRV stands at 62.2M. In comparison, MDGL has a market cap of 12.1B. Regarding current trading prices, ACRV is priced at $1.97, while MDGL trades at $529.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACRV currently has a P/E ratio of -0.98, whereas MDGL's P/E ratio is -41.15. In terms of profitability, ACRV's ROE is -0.57%, compared to MDGL's ROE of -0.44%. Regarding short-term risk, ACRV is more volatile compared to MDGL. This indicates potentially higher risk in terms of short-term price fluctuations for ACRV.Check MDGL's competition here
ACRV vs RNAM Comparison April 2026
ACRV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACRV stands at 62.2M. In comparison, RNAM has a market cap of 11.3B. Regarding current trading prices, ACRV is priced at $1.97, while RNAM trades at $72.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACRV currently has a P/E ratio of -0.98, whereas RNAM's P/E ratio is -17.39. In terms of profitability, ACRV's ROE is -0.57%, compared to RNAM's ROE of -0.45%. Regarding short-term risk, ACRV is more volatile compared to RNAM. This indicates potentially higher risk in terms of short-term price fluctuations for ACRV.Check RNAM's competition here
ACRV vs BMRN Comparison April 2026
ACRV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACRV stands at 62.2M. In comparison, BMRN has a market cap of 10.4B. Regarding current trading prices, ACRV is priced at $1.97, while BMRN trades at $54.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACRV currently has a P/E ratio of -0.98, whereas BMRN's P/E ratio is 30.08. In terms of profitability, ACRV's ROE is -0.57%, compared to BMRN's ROE of +0.06%. Regarding short-term risk, ACRV is more volatile compared to BMRN. This indicates potentially higher risk in terms of short-term price fluctuations for ACRV.Check BMRN's competition here
ACRV vs ARWR Comparison April 2026
ACRV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACRV stands at 62.2M. In comparison, ARWR has a market cap of 10.4B. Regarding current trading prices, ACRV is priced at $1.97, while ARWR trades at $73.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACRV currently has a P/E ratio of -0.98, whereas ARWR's P/E ratio is 46.20. In terms of profitability, ACRV's ROE is -0.57%, compared to ARWR's ROE of +0.36%. Regarding short-term risk, ACRV is more volatile compared to ARWR. This indicates potentially higher risk in terms of short-term price fluctuations for ACRV.Check ARWR's competition here
ACRV vs RXDX Comparison April 2026
ACRV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACRV stands at 62.2M. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, ACRV is priced at $1.97, while RXDX trades at $199.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACRV currently has a P/E ratio of -0.98, whereas RXDX's P/E ratio is -56.47. In terms of profitability, ACRV's ROE is -0.57%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, ACRV is more volatile compared to RXDX. This indicates potentially higher risk in terms of short-term price fluctuations for ACRV.Check RXDX's competition here
ACRV vs AXSM Comparison April 2026
ACRV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACRV stands at 62.2M. In comparison, AXSM has a market cap of 9.5B. Regarding current trading prices, ACRV is priced at $1.97, while AXSM trades at $186.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACRV currently has a P/E ratio of -0.98, whereas AXSM's P/E ratio is -50.52. In terms of profitability, ACRV's ROE is -0.57%, compared to AXSM's ROE of -2.54%. Regarding short-term risk, ACRV is more volatile compared to AXSM. This indicates potentially higher risk in terms of short-term price fluctuations for ACRV.Check AXSM's competition here
ACRV vs TECH Comparison April 2026
ACRV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACRV stands at 62.2M. In comparison, TECH has a market cap of 9.2B. Regarding current trading prices, ACRV is priced at $1.97, while TECH trades at $58.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACRV currently has a P/E ratio of -0.98, whereas TECH's P/E ratio is 108.48. In terms of profitability, ACRV's ROE is -0.57%, compared to TECH's ROE of +0.04%. Regarding short-term risk, ACRV is more volatile compared to TECH. This indicates potentially higher risk in terms of short-term price fluctuations for ACRV.Check TECH's competition here
ACRV vs PCVX Comparison April 2026
ACRV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACRV stands at 62.2M. In comparison, PCVX has a market cap of 8.8B. Regarding current trading prices, ACRV is priced at $1.97, while PCVX trades at $60.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACRV currently has a P/E ratio of -0.98, whereas PCVX's P/E ratio is -10.80. In terms of profitability, ACRV's ROE is -0.57%, compared to PCVX's ROE of -0.26%. Regarding short-term risk, ACRV is more volatile compared to PCVX. This indicates potentially higher risk in terms of short-term price fluctuations for ACRV.Check PCVX's competition here
ACRV vs IMGN Comparison April 2026
ACRV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACRV stands at 62.2M. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, ACRV is priced at $1.97, while IMGN trades at $31.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACRV currently has a P/E ratio of -0.98, whereas IMGN's P/E ratio is -111.55. In terms of profitability, ACRV's ROE is -0.57%, compared to IMGN's ROE of -0.93%. Regarding short-term risk, ACRV is more volatile compared to IMGN. This indicates potentially higher risk in terms of short-term price fluctuations for ACRV.Check IMGN's competition here
ACRV vs BPMC Comparison April 2026
ACRV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACRV stands at 62.2M. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, ACRV is priced at $1.97, while BPMC trades at $129.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACRV currently has a P/E ratio of -0.98, whereas BPMC's P/E ratio is -51.58. In terms of profitability, ACRV's ROE is -0.57%, compared to BPMC's ROE of -0.15%. Regarding short-term risk, ACRV is more volatile compared to BPMC. This indicates potentially higher risk in terms of short-term price fluctuations for ACRV.Check BPMC's competition here
ACRV vs IBRX Comparison April 2026
ACRV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACRV stands at 62.2M. In comparison, IBRX has a market cap of 8.3B. Regarding current trading prices, ACRV is priced at $1.97, while IBRX trades at $8.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACRV currently has a P/E ratio of -0.98, whereas IBRX's P/E ratio is -21.24. In terms of profitability, ACRV's ROE is -0.57%, compared to IBRX's ROE of +0.64%. Regarding short-term risk, ACRV is more volatile compared to IBRX. This indicates potentially higher risk in terms of short-term price fluctuations for ACRV.Check IBRX's competition here
ACRV vs CERE Comparison April 2026
ACRV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACRV stands at 62.2M. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, ACRV is priced at $1.97, while CERE trades at $44.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACRV currently has a P/E ratio of -0.98, whereas CERE's P/E ratio is -16.47. In terms of profitability, ACRV's ROE is -0.57%, compared to CERE's ROE of -0.72%. Regarding short-term risk, ACRV is more volatile compared to CERE. This indicates potentially higher risk in terms of short-term price fluctuations for ACRV.Check CERE's competition here
ACRV vs CYTK Comparison April 2026
ACRV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACRV stands at 62.2M. In comparison, CYTK has a market cap of 8.2B. Regarding current trading prices, ACRV is priced at $1.97, while CYTK trades at $66.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACRV currently has a P/E ratio of -0.98, whereas CYTK's P/E ratio is -10.13. In terms of profitability, ACRV's ROE is -0.57%, compared to CYTK's ROE of +1.73%. Regarding short-term risk, ACRV is more volatile compared to CYTK. This indicates potentially higher risk in terms of short-term price fluctuations for ACRV.Check CYTK's competition here
ACRV vs HALO Comparison April 2026
ACRV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACRV stands at 62.2M. In comparison, HALO has a market cap of 8.1B. Regarding current trading prices, ACRV is priced at $1.97, while HALO trades at $68.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACRV currently has a P/E ratio of -0.98, whereas HALO's P/E ratio is 26.72. In terms of profitability, ACRV's ROE is -0.57%, compared to HALO's ROE of +0.93%. Regarding short-term risk, ACRV is more volatile compared to HALO. This indicates potentially higher risk in terms of short-term price fluctuations for ACRV.Check HALO's competition here
ACRV vs KRYS Comparison April 2026
ACRV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACRV stands at 62.2M. In comparison, KRYS has a market cap of 8.1B. Regarding current trading prices, ACRV is priced at $1.97, while KRYS trades at $275.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACRV currently has a P/E ratio of -0.98, whereas KRYS's P/E ratio is 40.40. In terms of profitability, ACRV's ROE is -0.57%, compared to KRYS's ROE of +0.19%. Regarding short-term risk, ACRV is more volatile compared to KRYS. This indicates potentially higher risk in terms of short-term price fluctuations for ACRV.Check KRYS's competition here
ACRV vs NUVL Comparison April 2026
ACRV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACRV stands at 62.2M. In comparison, NUVL has a market cap of 8B. Regarding current trading prices, ACRV is priced at $1.97, while NUVL trades at $108.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACRV currently has a P/E ratio of -0.98, whereas NUVL's P/E ratio is -18.61. In terms of profitability, ACRV's ROE is -0.57%, compared to NUVL's ROE of -0.42%. Regarding short-term risk, ACRV is more volatile compared to NUVL. This indicates potentially higher risk in terms of short-term price fluctuations for ACRV.Check NUVL's competition here
ACRV vs ABVX Comparison April 2026
ACRV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACRV stands at 62.2M. In comparison, ABVX has a market cap of 7.6B. Regarding current trading prices, ACRV is priced at $1.97, while ABVX trades at $115.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACRV currently has a P/E ratio of -0.98, whereas ABVX's P/E ratio is -20.31. In terms of profitability, ACRV's ROE is -0.57%, compared to ABVX's ROE of -1.59%. Regarding short-term risk, ACRV is more volatile compared to ABVX. This indicates potentially higher risk in terms of short-term price fluctuations for ACRV.Check ABVX's competition here
ACRV vs MTSR Comparison April 2026
ACRV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACRV stands at 62.2M. In comparison, MTSR has a market cap of 7.4B. Regarding current trading prices, ACRV is priced at $1.97, while MTSR trades at $70.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACRV currently has a P/E ratio of -0.98, whereas MTSR's P/E ratio is -23.58. In terms of profitability, ACRV's ROE is -0.57%, compared to MTSR's ROE of -0.80%. Regarding short-term risk, ACRV is more volatile compared to MTSR. This indicates potentially higher risk in terms of short-term price fluctuations for ACRV.Check MTSR's competition here
ACRV vs KYMR Comparison April 2026
ACRV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACRV stands at 62.2M. In comparison, KYMR has a market cap of 7.2B. Regarding current trading prices, ACRV is priced at $1.97, while KYMR trades at $88.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACRV currently has a P/E ratio of -0.98, whereas KYMR's P/E ratio is -24.06. In terms of profitability, ACRV's ROE is -0.57%, compared to KYMR's ROE of -0.29%. Regarding short-term risk, ACRV is more volatile compared to KYMR. This indicates potentially higher risk in terms of short-term price fluctuations for ACRV.Check KYMR's competition here
ACRV vs PRAX Comparison April 2026
ACRV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACRV stands at 62.2M. In comparison, PRAX has a market cap of 7.1B. Regarding current trading prices, ACRV is priced at $1.97, while PRAX trades at $337.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACRV currently has a P/E ratio of -0.98, whereas PRAX's P/E ratio is -25.02. In terms of profitability, ACRV's ROE is -0.57%, compared to PRAX's ROE of -0.59%. Regarding short-term risk, ACRV is more volatile compared to PRAX. This indicates potentially higher risk in terms of short-term price fluctuations for ACRV.Check PRAX's competition here
ACRV vs MRUS Comparison April 2026
ACRV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACRV stands at 62.2M. In comparison, MRUS has a market cap of 6.8B. Regarding current trading prices, ACRV is priced at $1.97, while MRUS trades at $90.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACRV currently has a P/E ratio of -0.98, whereas MRUS's P/E ratio is -17.05. In terms of profitability, ACRV's ROE is -0.57%, compared to MRUS's ROE of -0.51%. Regarding short-term risk, ACRV is more volatile compared to MRUS. This indicates potentially higher risk in terms of short-term price fluctuations for ACRV.Check MRUS's competition here
ACRV vs PTGX Comparison April 2026
ACRV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACRV stands at 62.2M. In comparison, PTGX has a market cap of 6.7B. Regarding current trading prices, ACRV is priced at $1.97, while PTGX trades at $105.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACRV currently has a P/E ratio of -0.98, whereas PTGX's P/E ratio is -51.49. In terms of profitability, ACRV's ROE is -0.57%, compared to PTGX's ROE of -0.20%. Regarding short-term risk, ACRV is more volatile compared to PTGX. This indicates potentially higher risk in terms of short-term price fluctuations for ACRV.Check PTGX's competition here
ACRV vs ERAS Comparison April 2026
ACRV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACRV stands at 62.2M. In comparison, ERAS has a market cap of 6.7B. Regarding current trading prices, ACRV is priced at $1.97, while ERAS trades at $21.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACRV currently has a P/E ratio of -0.98, whereas ERAS's P/E ratio is -49.20. In terms of profitability, ACRV's ROE is -0.57%, compared to ERAS's ROE of -0.34%. Regarding short-term risk, ACRV is more volatile compared to ERAS. This indicates potentially higher risk in terms of short-term price fluctuations for ACRV.Check ERAS's competition here
ACRV vs ACLX Comparison April 2026
ACRV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACRV stands at 62.2M. In comparison, ACLX has a market cap of 6.7B. Regarding current trading prices, ACRV is priced at $1.97, while ACLX trades at $115.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACRV currently has a P/E ratio of -0.98, whereas ACLX's P/E ratio is -28.26. In terms of profitability, ACRV's ROE is -0.57%, compared to ACLX's ROE of -0.55%. Regarding short-term risk, ACRV is more volatile compared to ACLX. This indicates potentially higher risk in terms of short-term price fluctuations for ACRV.Check ACLX's competition here
ACRV vs BLTE Comparison April 2026
ACRV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACRV stands at 62.2M. In comparison, BLTE has a market cap of 6.7B. Regarding current trading prices, ACRV is priced at $1.97, while BLTE trades at $167.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACRV currently has a P/E ratio of -0.98, whereas BLTE's P/E ratio is -72.16. In terms of profitability, ACRV's ROE is -0.57%, compared to BLTE's ROE of -0.23%. Regarding short-term risk, ACRV is more volatile compared to BLTE. This indicates potentially higher risk in terms of short-term price fluctuations for ACRV.Check BLTE's competition here
ACRV vs RETA Comparison April 2026
ACRV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACRV stands at 62.2M. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, ACRV is priced at $1.97, while RETA trades at $172.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACRV currently has a P/E ratio of -0.98, whereas RETA's P/E ratio is -66.29. In terms of profitability, ACRV's ROE is -0.57%, compared to RETA's ROE of +0.47%. Regarding short-term risk, ACRV is more volatile compared to RETA. This indicates potentially higher risk in terms of short-term price fluctuations for ACRV.Check RETA's competition here
ACRV vs TGTX Comparison April 2026
ACRV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACRV stands at 62.2M. In comparison, TGTX has a market cap of 6.1B. Regarding current trading prices, ACRV is priced at $1.97, while TGTX trades at $38.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACRV currently has a P/E ratio of -0.98, whereas TGTX's P/E ratio is 13.83. In terms of profitability, ACRV's ROE is -0.57%, compared to TGTX's ROE of +1.01%. Regarding short-term risk, ACRV is more volatile compared to TGTX. This indicates potentially higher risk in terms of short-term price fluctuations for ACRV.Check TGTX's competition here
ACRV vs IMVT Comparison April 2026
ACRV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACRV stands at 62.2M. In comparison, IMVT has a market cap of 6B. Regarding current trading prices, ACRV is priced at $1.97, while IMVT trades at $29.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACRV currently has a P/E ratio of -0.98, whereas IMVT's P/E ratio is -11.04. In terms of profitability, ACRV's ROE is -0.57%, compared to IMVT's ROE of -0.66%. Regarding short-term risk, ACRV is more volatile compared to IMVT. This indicates potentially higher risk in terms of short-term price fluctuations for ACRV.Check IMVT's competition here
ACRV vs CELC Comparison April 2026
ACRV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACRV stands at 62.2M. In comparison, CELC has a market cap of 5.9B. Regarding current trading prices, ACRV is priced at $1.97, while CELC trades at $122.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACRV currently has a P/E ratio of -0.98, whereas CELC's P/E ratio is -32.22. In terms of profitability, ACRV's ROE is -0.57%, compared to CELC's ROE of -2.03%. Regarding short-term risk, ACRV is more volatile compared to CELC. This indicates potentially higher risk in terms of short-term price fluctuations for ACRV.Check CELC's competition here
ACRV vs COGT Comparison April 2026
ACRV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACRV stands at 62.2M. In comparison, COGT has a market cap of 5.9B. Regarding current trading prices, ACRV is priced at $1.97, while COGT trades at $36.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACRV currently has a P/E ratio of -0.98, whereas COGT's P/E ratio is -16.85. In terms of profitability, ACRV's ROE is -0.57%, compared to COGT's ROE of -1.00%. Regarding short-term risk, ACRV is more volatile compared to COGT. This indicates potentially higher risk in terms of short-term price fluctuations for ACRV.Check COGT's competition here
ACRV vs CGON Comparison April 2026
ACRV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACRV stands at 62.2M. In comparison, CGON has a market cap of 5.9B. Regarding current trading prices, ACRV is priced at $1.97, while CGON trades at $69.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACRV currently has a P/E ratio of -0.98, whereas CGON's P/E ratio is -33.60. In terms of profitability, ACRV's ROE is -0.57%, compared to CGON's ROE of -0.23%. Regarding short-term risk, ACRV is more volatile compared to CGON. This indicates potentially higher risk in terms of short-term price fluctuations for ACRV.Check CGON's competition here
ACRV vs CNTA Comparison April 2026
ACRV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACRV stands at 62.2M. In comparison, CNTA has a market cap of 5.9B. Regarding current trading prices, ACRV is priced at $1.97, while CNTA trades at $39.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACRV currently has a P/E ratio of -0.98, whereas CNTA's P/E ratio is -27.03. In terms of profitability, ACRV's ROE is -0.57%, compared to CNTA's ROE of -0.51%. Regarding short-term risk, ACRV is more volatile compared to CNTA. This indicates potentially higher risk in terms of short-term price fluctuations for ACRV.Check CNTA's competition here
ACRV vs PTCT Comparison April 2026
ACRV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACRV stands at 62.2M. In comparison, PTCT has a market cap of 5.9B. Regarding current trading prices, ACRV is priced at $1.97, while PTCT trades at $70.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACRV currently has a P/E ratio of -0.98, whereas PTCT's P/E ratio is 8.26. In terms of profitability, ACRV's ROE is -0.57%, compared to PTCT's ROE of -3.62%. Regarding short-term risk, ACRV is more volatile compared to PTCT. This indicates potentially higher risk in terms of short-term price fluctuations for ACRV.Check PTCT's competition here
ACRV vs RYTM Comparison April 2026
ACRV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACRV stands at 62.2M. In comparison, RYTM has a market cap of 5.8B. Regarding current trading prices, ACRV is priced at $1.97, while RYTM trades at $85.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACRV currently has a P/E ratio of -0.98, whereas RYTM's P/E ratio is -27.39. In terms of profitability, ACRV's ROE is -0.57%, compared to RYTM's ROE of -1.79%. Regarding short-term risk, ACRV is more volatile compared to RYTM. This indicates potentially higher risk in terms of short-term price fluctuations for ACRV.Check RYTM's competition here
ACRV vs CAI Comparison April 2026
ACRV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACRV stands at 62.2M. In comparison, CAI has a market cap of 5.8B. Regarding current trading prices, ACRV is priced at $1.97, while CAI trades at $20.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACRV currently has a P/E ratio of -0.98, whereas CAI's P/E ratio is -6.37. In terms of profitability, ACRV's ROE is -0.57%, compared to CAI's ROE of +0.25%. Regarding short-term risk, ACRV is more volatile compared to CAI. This indicates potentially higher risk in terms of short-term price fluctuations for ACRV.Check CAI's competition here
ACRV vs ALKS Comparison April 2026
ACRV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACRV stands at 62.2M. In comparison, ALKS has a market cap of 5.6B. Regarding current trading prices, ACRV is priced at $1.97, while ALKS trades at $33.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACRV currently has a P/E ratio of -0.98, whereas ALKS's P/E ratio is 23.59. In terms of profitability, ACRV's ROE is -0.57%, compared to ALKS's ROE of +0.14%. Regarding short-term risk, ACRV is more volatile compared to ALKS. This indicates potentially higher risk in terms of short-term price fluctuations for ACRV.Check ALKS's competition here
ACRV vs CDTX Comparison April 2026
ACRV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACRV stands at 62.2M. In comparison, CDTX has a market cap of 5.6B. Regarding current trading prices, ACRV is priced at $1.97, while CDTX trades at $221.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACRV currently has a P/E ratio of -0.98, whereas CDTX's P/E ratio is -19.77. In terms of profitability, ACRV's ROE is -0.57%, compared to CDTX's ROE of -0.60%. Regarding short-term risk, ACRV is more volatile compared to CDTX. This indicates potentially higher risk in terms of short-term price fluctuations for ACRV.Check CDTX's competition here
ACRV vs ABCM Comparison April 2026
ACRV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACRV stands at 62.2M. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, ACRV is priced at $1.97, while ABCM trades at $23.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACRV currently has a P/E ratio of -0.98, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, ACRV's ROE is -0.57%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, ACRV is more volatile compared to ABCM. This indicates potentially higher risk in terms of short-term price fluctuations for ACRV.Check ABCM's competition here
ACRV vs ISEE Comparison April 2026
ACRV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACRV stands at 62.2M. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, ACRV is priced at $1.97, while ISEE trades at $39.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACRV currently has a P/E ratio of -0.98, whereas ISEE's P/E ratio is -22.44. In terms of profitability, ACRV's ROE is -0.57%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, ACRV is more volatile compared to ISEE. This indicates potentially higher risk in terms of short-term price fluctuations for ACRV.Check ISEE's competition here
ACRV vs SRRK Comparison April 2026
ACRV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACRV stands at 62.2M. In comparison, SRRK has a market cap of 5.4B. Regarding current trading prices, ACRV is priced at $1.97, while SRRK trades at $47.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACRV currently has a P/E ratio of -0.98, whereas SRRK's P/E ratio is -14.39. In terms of profitability, ACRV's ROE is -0.57%, compared to SRRK's ROE of -1.46%. Regarding short-term risk, ACRV is more volatile compared to SRRK. This indicates potentially higher risk in terms of short-term price fluctuations for ACRV.Check SRRK's competition here
ACRV vs CRSP Comparison April 2026
ACRV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACRV stands at 62.2M. In comparison, CRSP has a market cap of 5.4B. Regarding current trading prices, ACRV is priced at $1.97, while CRSP trades at $56.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACRV currently has a P/E ratio of -0.98, whereas CRSP's P/E ratio is -8.72. In terms of profitability, ACRV's ROE is -0.57%, compared to CRSP's ROE of -0.32%. Regarding short-term risk, ACRV is more volatile compared to CRSP. This indicates potentially higher risk in terms of short-term price fluctuations for ACRV.Check CRSP's competition here
ACRV vs APLS Comparison April 2026
ACRV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACRV stands at 62.2M. In comparison, APLS has a market cap of 5.2B. Regarding current trading prices, ACRV is priced at $1.97, while APLS trades at $40.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACRV currently has a P/E ratio of -0.98, whereas APLS's P/E ratio is 227.17. In terms of profitability, ACRV's ROE is -0.57%, compared to APLS's ROE of +0.08%. Regarding short-term risk, ACRV is more volatile compared to APLS. This indicates potentially higher risk in terms of short-term price fluctuations for ACRV.Check APLS's competition here
ACRV vs FBIOX Comparison April 2026
ACRV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACRV stands at 62.2M. In comparison, FBIOX has a market cap of 5.2B. Regarding current trading prices, ACRV is priced at $1.97, while FBIOX trades at $25.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACRV currently has a P/E ratio of -0.98, whereas FBIOX's P/E ratio is N/A. In terms of profitability, ACRV's ROE is -0.57%, compared to FBIOX's ROE of +0.00%. Regarding short-term risk, ACRV is more volatile compared to FBIOX. This indicates potentially higher risk in terms of short-term price fluctuations for ACRV.Check FBIOX's competition here
ACRV vs APGE Comparison April 2026
ACRV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACRV stands at 62.2M. In comparison, APGE has a market cap of 5.1B. Regarding current trading prices, ACRV is priced at $1.97, while APGE trades at $90.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACRV currently has a P/E ratio of -0.98, whereas APGE's P/E ratio is -21.49. In terms of profitability, ACRV's ROE is -0.57%, compared to APGE's ROE of -0.37%. Regarding short-term risk, ACRV is more volatile compared to APGE. This indicates potentially higher risk in terms of short-term price fluctuations for ACRV.Check APGE's competition here
ACRV vs CORT Comparison April 2026
ACRV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACRV stands at 62.2M. In comparison, CORT has a market cap of 5B. Regarding current trading prices, ACRV is priced at $1.97, while CORT trades at $46.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACRV currently has a P/E ratio of -0.98, whereas CORT's P/E ratio is 56.79. In terms of profitability, ACRV's ROE is -0.57%, compared to CORT's ROE of +0.15%. Regarding short-term risk, ACRV is more volatile compared to CORT. This indicates potentially higher risk in terms of short-term price fluctuations for ACRV.Check CORT's competition here
ACRV vs LEGN Comparison April 2026
ACRV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACRV stands at 62.2M. In comparison, LEGN has a market cap of 4.8B. Regarding current trading prices, ACRV is priced at $1.97, while LEGN trades at $25.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACRV currently has a P/E ratio of -0.98, whereas LEGN's P/E ratio is -16.01. In terms of profitability, ACRV's ROE is -0.57%, compared to LEGN's ROE of -0.29%. Regarding short-term risk, ACRV is more volatile compared to LEGN. This indicates potentially higher risk in terms of short-term price fluctuations for ACRV.Check LEGN's competition here
ACRV vs TERN Comparison April 2026
ACRV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACRV stands at 62.2M. In comparison, TERN has a market cap of 4.8B. Regarding current trading prices, ACRV is priced at $1.97, while TERN trades at $52.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACRV currently has a P/E ratio of -0.98, whereas TERN's P/E ratio is -51.30. In terms of profitability, ACRV's ROE is -0.57%, compared to TERN's ROE of -0.20%. Regarding short-term risk, ACRV is more volatile compared to TERN. This indicates potentially higher risk in terms of short-term price fluctuations for ACRV.Check TERN's competition here
ACRV vs MIRM Comparison April 2026
ACRV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACRV stands at 62.2M. In comparison, MIRM has a market cap of 4.7B. Regarding current trading prices, ACRV is priced at $1.97, while MIRM trades at $94.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACRV currently has a P/E ratio of -0.98, whereas MIRM's P/E ratio is -200.66. In terms of profitability, ACRV's ROE is -0.57%, compared to MIRM's ROE of -0.09%. Regarding short-term risk, ACRV is more volatile compared to MIRM. This indicates potentially higher risk in terms of short-term price fluctuations for ACRV.Check MIRM's competition here
ACRV vs FOLD Comparison April 2026
ACRV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACRV stands at 62.2M. In comparison, FOLD has a market cap of 4.5B. Regarding current trading prices, ACRV is priced at $1.97, while FOLD trades at $14.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACRV currently has a P/E ratio of -0.98, whereas FOLD's P/E ratio is -160.67. In terms of profitability, ACRV's ROE is -0.57%, compared to FOLD's ROE of -0.12%. Regarding short-term risk, ACRV is more volatile compared to FOLD. This indicates potentially higher risk in terms of short-term price fluctuations for ACRV.Check FOLD's competition here
ACRV vs LGND Comparison April 2026
ACRV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACRV stands at 62.2M. In comparison, LGND has a market cap of 4.5B. Regarding current trading prices, ACRV is priced at $1.97, while LGND trades at $226.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACRV currently has a P/E ratio of -0.98, whereas LGND's P/E ratio is 37.01. In terms of profitability, ACRV's ROE is -0.57%, compared to LGND's ROE of +0.14%. Regarding short-term risk, ACRV is more volatile compared to LGND. This indicates potentially higher risk in terms of short-term price fluctuations for ACRV.Check LGND's competition here
ACRV vs AKRO Comparison April 2026
ACRV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACRV stands at 62.2M. In comparison, AKRO has a market cap of 4.5B. Regarding current trading prices, ACRV is priced at $1.97, while AKRO trades at $54.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACRV currently has a P/E ratio of -0.98, whereas AKRO's P/E ratio is -14.57. In terms of profitability, ACRV's ROE is -0.57%, compared to AKRO's ROE of -0.31%. Regarding short-term risk, ACRV is more volatile compared to AKRO. This indicates potentially higher risk in terms of short-term price fluctuations for ACRV.Check AKRO's competition here
ACRV vs XENE Comparison April 2026
ACRV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACRV stands at 62.2M. In comparison, XENE has a market cap of 4.5B. Regarding current trading prices, ACRV is priced at $1.97, while XENE trades at $56.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACRV currently has a P/E ratio of -0.98, whereas XENE's P/E ratio is -12.99. In terms of profitability, ACRV's ROE is -0.57%, compared to XENE's ROE of -0.56%. Regarding short-term risk, ACRV is more volatile compared to XENE. This indicates potentially higher risk in terms of short-term price fluctuations for ACRV.Check XENE's competition here
ACRV vs ALPN Comparison April 2026
ACRV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACRV stands at 62.2M. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, ACRV is priced at $1.97, while ALPN trades at $64.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACRV currently has a P/E ratio of -0.98, whereas ALPN's P/E ratio is -101.52. In terms of profitability, ACRV's ROE is -0.57%, compared to ALPN's ROE of -0.13%. Regarding short-term risk, ACRV is more volatile compared to ALPN. This indicates potentially higher risk in terms of short-term price fluctuations for ACRV.Check ALPN's competition here
ACRV vs SYRE Comparison April 2026
ACRV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACRV stands at 62.2M. In comparison, SYRE has a market cap of 4.4B. Regarding current trading prices, ACRV is priced at $1.97, while SYRE trades at $73.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACRV currently has a P/E ratio of -0.98, whereas SYRE's P/E ratio is -36.87. In terms of profitability, ACRV's ROE is -0.57%, compared to SYRE's ROE of -0.29%. Regarding short-term risk, ACRV is more volatile compared to SYRE. This indicates potentially higher risk in terms of short-term price fluctuations for ACRV.Check SYRE's competition here
ACRV vs OPT Comparison April 2026
ACRV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACRV stands at 62.2M. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, ACRV is priced at $1.97, while OPT trades at $3.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACRV currently has a P/E ratio of -0.98, whereas OPT's P/E ratio is -1.52. In terms of profitability, ACRV's ROE is -0.57%, compared to OPT's ROE of +0.88%. Regarding short-term risk, ACRV is more volatile compared to OPT. This indicates potentially higher risk in terms of short-term price fluctuations for ACRV.Check OPT's competition here
ACRV vs MRTX Comparison April 2026
ACRV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACRV stands at 62.2M. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, ACRV is priced at $1.97, while MRTX trades at $58.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACRV currently has a P/E ratio of -0.98, whereas MRTX's P/E ratio is -4.82. In terms of profitability, ACRV's ROE is -0.57%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, ACRV is more volatile compared to MRTX. This indicates potentially higher risk in terms of short-term price fluctuations for ACRV.Check MRTX's competition here
ACRV vs CRNX Comparison April 2026
ACRV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACRV stands at 62.2M. In comparison, CRNX has a market cap of 4.1B. Regarding current trading prices, ACRV is priced at $1.97, while CRNX trades at $39.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACRV currently has a P/E ratio of -0.98, whereas CRNX's P/E ratio is -7.90. In terms of profitability, ACRV's ROE is -0.57%, compared to CRNX's ROE of -0.41%. Regarding short-term risk, ACRV is more volatile compared to CRNX. This indicates potentially higher risk in terms of short-term price fluctuations for ACRV.Check CRNX's competition here
ACRV vs VKTX Comparison April 2026
ACRV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACRV stands at 62.2M. In comparison, VKTX has a market cap of 4B. Regarding current trading prices, ACRV is priced at $1.97, while VKTX trades at $34.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACRV currently has a P/E ratio of -0.98, whereas VKTX's P/E ratio is -10.74. In terms of profitability, ACRV's ROE is -0.57%, compared to VKTX's ROE of -0.48%. Regarding short-term risk, ACRV is more volatile compared to VKTX. This indicates potentially higher risk in terms of short-term price fluctuations for ACRV.Check VKTX's competition here
ACRV vs ACAD Comparison April 2026
ACRV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACRV stands at 62.2M. In comparison, ACAD has a market cap of 3.8B. Regarding current trading prices, ACRV is priced at $1.97, while ACAD trades at $22.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACRV currently has a P/E ratio of -0.98, whereas ACAD's P/E ratio is 9.67. In terms of profitability, ACRV's ROE is -0.57%, compared to ACAD's ROE of +0.42%. Regarding short-term risk, ACRV is more volatile compared to ACAD. This indicates potentially higher risk in terms of short-term price fluctuations for ACRV.Check ACAD's competition here
ACRV vs RYZB Comparison April 2026
ACRV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACRV stands at 62.2M. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, ACRV is priced at $1.97, while RYZB trades at $62.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACRV currently has a P/E ratio of -0.98, whereas RYZB's P/E ratio is -57.86. In terms of profitability, ACRV's ROE is -0.57%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, ACRV is more volatile compared to RYZB. This indicates potentially higher risk in terms of short-term price fluctuations for ACRV.Check RYZB's competition here
ACRV vs CBAY Comparison April 2026
ACRV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACRV stands at 62.2M. In comparison, CBAY has a market cap of 3.7B. Regarding current trading prices, ACRV is priced at $1.97, while CBAY trades at $32.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACRV currently has a P/E ratio of -0.98, whereas CBAY's P/E ratio is -32.81. In terms of profitability, ACRV's ROE is -0.57%, compared to CBAY's ROE of -0.64%. Regarding short-term risk, ACRV is more volatile compared to CBAY. This indicates potentially higher risk in terms of short-term price fluctuations for ACRV.Check CBAY's competition here
ACRV vs TVTX Comparison April 2026
ACRV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACRV stands at 62.2M. In comparison, TVTX has a market cap of 3.7B. Regarding current trading prices, ACRV is priced at $1.97, while TVTX trades at $40.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACRV currently has a P/E ratio of -0.98, whereas TVTX's P/E ratio is -70.33. In terms of profitability, ACRV's ROE is -0.57%, compared to TVTX's ROE of -0.79%. Regarding short-term risk, ACRV is more volatile compared to TVTX. This indicates potentially higher risk in terms of short-term price fluctuations for ACRV.Check TVTX's competition here
ACRV vs NAMS Comparison April 2026
ACRV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACRV stands at 62.2M. In comparison, NAMS has a market cap of 3.7B. Regarding current trading prices, ACRV is priced at $1.97, while NAMS trades at $31.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACRV currently has a P/E ratio of -0.98, whereas NAMS's P/E ratio is -18.57. In terms of profitability, ACRV's ROE is -0.57%, compared to NAMS's ROE of -0.27%. Regarding short-term risk, ACRV is more volatile compared to NAMS. This indicates potentially higher risk in terms of short-term price fluctuations for ACRV.Check NAMS's competition here
ACRV vs SWTX Comparison April 2026
ACRV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACRV stands at 62.2M. In comparison, SWTX has a market cap of 3.5B. Regarding current trading prices, ACRV is priced at $1.97, while SWTX trades at $46.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACRV currently has a P/E ratio of -0.98, whereas SWTX's P/E ratio is -13.78. In terms of profitability, ACRV's ROE is -0.57%, compared to SWTX's ROE of -0.36%. Regarding short-term risk, ACRV is more volatile compared to SWTX. This indicates potentially higher risk in terms of short-term price fluctuations for ACRV.Check SWTX's competition here
ACRV vs DNTH Comparison April 2026
ACRV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACRV stands at 62.2M. In comparison, DNTH has a market cap of 3.5B. Regarding current trading prices, ACRV is priced at $1.97, while DNTH trades at $91.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACRV currently has a P/E ratio of -0.98, whereas DNTH's P/E ratio is -21.74. In terms of profitability, ACRV's ROE is -0.57%, compared to DNTH's ROE of +0.00%. Regarding short-term risk, ACRV is more volatile compared to DNTH. This indicates potentially higher risk in terms of short-term price fluctuations for ACRV.Check DNTH's competition here
ACRV vs TLX Comparison April 2026
ACRV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACRV stands at 62.2M. In comparison, TLX has a market cap of 3.5B. Regarding current trading prices, ACRV is priced at $1.97, while TLX trades at $10.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACRV currently has a P/E ratio of -0.98, whereas TLX's P/E ratio is -516.50. In terms of profitability, ACRV's ROE is -0.57%, compared to TLX's ROE of -0.02%. Regarding short-term risk, ACRV is more volatile compared to TLX. This indicates potentially higher risk in terms of short-term price fluctuations for ACRV.Check TLX's competition here
ACRV vs EWTX Comparison April 2026
ACRV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACRV stands at 62.2M. In comparison, EWTX has a market cap of 3.5B. Regarding current trading prices, ACRV is priced at $1.97, while EWTX trades at $32.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACRV currently has a P/E ratio of -0.98, whereas EWTX's P/E ratio is -19.74. In terms of profitability, ACRV's ROE is -0.57%, compared to EWTX's ROE of -0.32%. Regarding short-term risk, ACRV is more volatile compared to EWTX. This indicates potentially higher risk in terms of short-term price fluctuations for ACRV.Check EWTX's competition here
ACRV vs LQDA Comparison April 2026
ACRV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACRV stands at 62.2M. In comparison, LQDA has a market cap of 3.3B. Regarding current trading prices, ACRV is priced at $1.97, while LQDA trades at $37.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACRV currently has a P/E ratio of -0.98, whereas LQDA's P/E ratio is -46.32. In terms of profitability, ACRV's ROE is -0.57%, compared to LQDA's ROE of -2.09%. Regarding short-term risk, ACRV is more volatile compared to LQDA. This indicates potentially higher risk in terms of short-term price fluctuations for ACRV.Check LQDA's competition here
ACRV vs DYN Comparison April 2026
ACRV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACRV stands at 62.2M. In comparison, DYN has a market cap of 3.2B. Regarding current trading prices, ACRV is priced at $1.97, while DYN trades at $19.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACRV currently has a P/E ratio of -0.98, whereas DYN's P/E ratio is -5.67. In terms of profitability, ACRV's ROE is -0.57%, compared to DYN's ROE of -0.61%. Regarding short-term risk, ACRV is more volatile compared to DYN. This indicates potentially higher risk in terms of short-term price fluctuations for ACRV.Check DYN's competition here
ACRV vs BEAM Comparison April 2026
ACRV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACRV stands at 62.2M. In comparison, BEAM has a market cap of 3.2B. Regarding current trading prices, ACRV is priced at $1.97, while BEAM trades at $31.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACRV currently has a P/E ratio of -0.98, whereas BEAM's P/E ratio is -39.12. In terms of profitability, ACRV's ROE is -0.57%, compared to BEAM's ROE of -0.07%. Regarding short-term risk, ACRV is more volatile compared to BEAM. This indicates potentially higher risk in terms of short-term price fluctuations for ACRV.Check BEAM's competition here
ACRV vs DNLI Comparison April 2026
ACRV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACRV stands at 62.2M. In comparison, DNLI has a market cap of 3.2B. Regarding current trading prices, ACRV is priced at $1.97, while DNLI trades at $20.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACRV currently has a P/E ratio of -0.98, whereas DNLI's P/E ratio is -6.82. In terms of profitability, ACRV's ROE is -0.57%, compared to DNLI's ROE of -0.50%. Regarding short-term risk, ACRV is more volatile compared to DNLI. This indicates potentially higher risk in terms of short-term price fluctuations for ACRV.Check DNLI's competition here
ACRV vs KNSA Comparison April 2026
ACRV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACRV stands at 62.2M. In comparison, KNSA has a market cap of 3.2B. Regarding current trading prices, ACRV is priced at $1.97, while KNSA trades at $43.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACRV currently has a P/E ratio of -0.98, whereas KNSA's P/E ratio is 57.39. In terms of profitability, ACRV's ROE is -0.57%, compared to KNSA's ROE of +0.11%. Regarding short-term risk, ACRV is more volatile compared to KNSA. This indicates potentially higher risk in terms of short-term price fluctuations for ACRV.Check KNSA's competition here
ACRV vs CPRX Comparison April 2026
ACRV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACRV stands at 62.2M. In comparison, CPRX has a market cap of 3.2B. Regarding current trading prices, ACRV is priced at $1.97, while CPRX trades at $25.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACRV currently has a P/E ratio of -0.98, whereas CPRX's P/E ratio is 15.26. In terms of profitability, ACRV's ROE is -0.57%, compared to CPRX's ROE of +0.24%. Regarding short-term risk, ACRV is more volatile compared to CPRX. This indicates potentially higher risk in terms of short-term price fluctuations for ACRV.Check CPRX's competition here
ACRV vs ALMS Comparison April 2026
ACRV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACRV stands at 62.2M. In comparison, ALMS has a market cap of 3.2B. Regarding current trading prices, ACRV is priced at $1.97, while ALMS trades at $25.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACRV currently has a P/E ratio of -0.98, whereas ALMS's P/E ratio is -9.05. In terms of profitability, ACRV's ROE is -0.57%, compared to ALMS's ROE of -0.73%. Regarding short-term risk, ACRV is more volatile compared to ALMS. This indicates potentially higher risk in terms of short-term price fluctuations for ACRV.Check ALMS's competition here
ACRV vs TNGX Comparison April 2026
ACRV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACRV stands at 62.2M. In comparison, TNGX has a market cap of 3.1B. Regarding current trading prices, ACRV is priced at $1.97, while TNGX trades at $26.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACRV currently has a P/E ratio of -0.98, whereas TNGX's P/E ratio is -30.97. In terms of profitability, ACRV's ROE is -0.57%, compared to TNGX's ROE of -0.50%. Regarding short-term risk, ACRV is more volatile compared to TNGX. This indicates potentially higher risk in terms of short-term price fluctuations for ACRV.Check TNGX's competition here